Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

Huge advantage with ANGPTL inhibitor for HoFH patients with minimal to zero LDLR activity
Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying PACE-CME…
but how about a more personalized experience?

Register for free